Association between influenza vaccination, all-cause mortality and cardiovascular mortality: a protocol for a living systematic review and prospective meta-analysis

Rong Liu, Anushka Patel, Xin Du, Hueiming Liu, Bette Liu, Chi Wang, Gian Luca Di Tanna

ABSTRACT

Introduction Influenza virus infection is known to increase the risk of cardiovascular events, especially in populations with pre-existing cardiovascular disease (CVD). Considering that influenza is vaccine preventable, international guidelines recommend high-risk populations with CVD receive an influenza vaccine every year. However, there are various classifications of recommendations and levels of evidence. Previous systematic reviews concluded uncertain evidence on influenza vaccine efficacy for preventing cardiovascular events in the general population or in populations with pre-existing CVD. Limited safety data of influenza vaccines were reported for populations with pre-existing CVD. Randomised controlled trials with larger sample sizes relative to previous studies are emerging, the findings of these trials are likely to be highly influential on summary efficacy estimates.

Methods and analysis We aim to perform a living systematic review and a prospective meta-analysis to evaluate the efficacy and safety of influenza vaccines compared with no vaccines or placebo for preventing mortality or CVD events in the general population and in populations with pre-existing CVD. Any types of randomised controlled trial and observational study meeting the Population, Intervention, Comparator, Outcome and Study design criteria for the research question will be selected for inclusion. The living systematic review status will be maintained for 3 years with an update for every 6 months. Mainstream medical literature databases will be independently searched by two authors with predefined strategies. Two authors will perform the risk of bias assessment with consensus. Narrative synthesis and meta-analyses will be performed to summarise the results.

Ethics and dissemination Formal ethical review is not required as this study does not involve primary data collection. We will publish results of the living systematic review and prospective meta-analysis in a peer-reviewed journal. Findings will also be presented at relevant meetings.

PROSPERO registration number CRD4202122519.

Strengths and limitations of this study

- The living systematic review will continually incorporate the latest research findings and keep the synthesised information updated.
- A prospective meta-analysis will better address this evolving evidence while minimising the risk of selective reporting and publication biases.
- In particular, the safety of influenza vaccines in populations with pre-existing cardiovascular diseases will be studied to augment the current evidence base.
- The inclusion of observational studies raises the potential limitations of confounding bias; however, we will perform subgroup meta-analysis by study design and present both randomised and non-randomised results.

INTRODUCTION

Influenza virus infection is known to increase the risk of cardiovascular events, especially in populations with pre-existing cardiovascular disease (CVD). The WHO recommends countries aim for 70% influenza vaccine coverage for high-risk groups, including the elderly and individuals with known chronic conditions.

CVD takes approximately 18 million lives each year, which accounts for one-third of all deaths worldwide. In order to achieve the global target of ‘25 by 25’ and ‘1/3 by 30’, reducing a quarter of premature deaths from Noncommunicable Disease (NCD) by 2025 and one-third of them by 2030, effective interventions need to be identified and implemented in the most vulnerable populations. The economic burden of CVD is projected to be more than $1 trillion in 2030, half of which relates to direct medical costs. Cost-effective interventions are needed to...
flattening the rising curve of healthcare costs for CVD. \(^4\)\(^5\) A modelling study showed a fully funded influenza vaccination programme compared with a self-paid one was cost-effective in a population over 60 years old in China, with vaccination coverage rate being 30% vs 0% respectively. An influenza vaccine coverage of 30% would avert 8800 influenza-associated excess deaths attributable to respiratory causes per year in China, which accounted for 98% of all costs from outpatient consultation, hospitalisation, death and loss of productivity.\(^6\)

Considering that influenza is vaccine preventable, international guidelines recommend high-risk populations with CVD receive an influenza vaccine every year, but there are various classifications of recommendations and levels of evidence.\(^7\)\(^8\) This uncertainty is reflected in the most recent 2015 Cochrane systematic review, which concluded uncertain evidence on influenza vaccine efficacy for preventing cardiovascular events in the general population or in populations with pre-existing CVD.\(^9\) The uncertainty derives from risks of bias in pooled studies and therefore higher quality evidence is needed to confirm the findings.

This Cochrane review included eight randomised controlled trials (RCTs) of influenza vaccine versus placebo or no vaccine with a total of 12,029 participants, and searched literature between the starting dates of database archive and October 2013. Their meta-analysis, pooling four of the included trials which assessed the association between influenza vaccination and cardiovascular mortality, showed a pooled risk ratio (RR) of 0.45 (95% CI 0.26 to 0.76, p=0.003). With more RCTs and a number of large-scale observational studies having been conducted since the Cochrane review, it is useful to update our understanding of the current evidence on influenza vaccines for preventing CVD events in both the general population and high-risk groups.\(^10\)\(^-\)\(^13\)

While the safety of influenza vaccines in the general population is well established, there is a paucity of safety data in populations with existing chronic disease. In these populations, current synthesised data on adverse event following immunisation or adverse health events that may be vaccine attributable are sparse.

Perhaps as a consequence of persistent uncertainty relating to both efficacy and safety, influenza vaccine coverage rates (VCR) are variable and often low in populations with pre-existing CVD. For example, recent influenza VCR in patients with heart failure (HF) ranges from nearly 0% in Asia to approximately 80% in Europe.\(^14\) In particular, most low and middle-income countries have not reached the target of 70% VCR set by WHO for high-risk groups. In China, the estimated influenza VCR for the entire population is 2% and is even lower (<1%) among high-risk groups.\(^14\)\(^15\) In a limited number of Chinese cities with a policy for free influenza vaccination among seniors, VCR in those older than 65 years is reported to be around 20%.\(^16\)

With the COVID-19 pandemic and mitigation measures such as facial masks, social distancing, lockdowns and travel restrictions, influenza activity globally was low in 2020. However, the potential for reduced population immunity due to low levels of circulating influenza, combined with countries reopening borders and relaxing mitigation measures in 2021, may lead to potential rebounds in rates of influenza infections.\(^17\)

As evidence from ongoing RCTs is still emerging, it is appropriate to conduct a living systematic review (LSR), which will continually incorporate the latest research findings and keep the synthesised information updated.\(^18\) Along with the LSR design, a prospective meta-analysis (PMA) will better address this evolving evidence. Through a PMA, we will aim to include studies to be published from December 2021 onwards to avoid potential bias.\(^19\)

**METHODS**

This protocol follows the 2015 Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement, along with the elaboration and explanation report, and the checklist.\(^20\)\(^21\)

**Objective**

The overall objective of this LSR is to evaluate the efficacy and safety of influenza vaccines compared with no vaccines or placebo for preventing mortality or CVD events in the general population and in high-risk populations with CVD.

**Eligibility criteria**

Studies selected for inclusion will meet the following Population, Intervention, Comparator, Outcome and Study design criteria.

**Population**

We will include studies focusing on the general population aged 18 years and above, or high-risk population with CVD. CVD is defined to include any diagnosis of hypertension (high blood pressure), coronary heart disease, cerebrovascular disease (stroke), peripheral vascular disease, HF, rheumatic heart disease, congenital heart disease (repaired or unrepaired), cardiomyopathies, valvular heart disease or atrial fibrillation. Studies focused on particular subgroups of the general population (e.g., healthcare workers or pregnant women) will not be excluded.

**Intervention**

We will include studies that investigate the effects of inactive influenza vaccine or live attenuated influenza vaccines during any influenza season, regardless of the valency, dose, administration route, boosts and use of concomitant vaccination strategies.

**Comparator**

We will include studies of no vaccine or placebo as comparators.
Outcomes

Outcomes of interest are all-cause mortality, cardiovascular-specific mortality, all-cause hospitalisation and cardiovascular-specific hospitalisation or events. Cardiovascular events include any diagnoses relating to myocardial infarction (MI), HF or stroke.

Types of studies

We will include any type of RCT (individually randomised, cluster, stepped wedge, other) and observational study (cohort and case-control). We will include published or accepted articles with RCT or observational designs without date limits. Preprints, theses or dissertations without formal peer review will not be included. No language restrictions will be imposed on the search strategies. We will include studies conducted in hospital-based, community-based or long-term care facility-based settings in both the Northern Hemisphere and Southern Hemisphere.

Time frame

We will include studies reporting outcomes with the follow-up period lasting an entire year after vaccination. The living status of the systematic review will be maintained for a minimum of 3 years after protocol publication. The baseline LSR and PMA are planned to start from December 2021. An update will be performed every 6 months after the baseline. At 3 months after previous reviews, an updated search will be performed. At 4 months after previous reviews, a reanalysis will be performed. At 5 months after previous reviews, an updated report will be drafted. Depending on the differences from previous reviews, the update will be considered to submit to peer-reviewed journals.

Information sources

We will search the following databases:

- Cochrane CENTRAL.
- ClinicalTrials.gov.
- Chinese Clinical Trial Registry (ChiCTR).
- Medline (PubMed interface).
- Embase (Ovid interface).
- CNKI.
- Wanfang.
- Database of Abstracts of Reviews of Effects (DARE).
- Economic Evaluation Database (EED).
- Health Technology Assessment (HTA).

Each database will be searched separately by two authors with an initial search strategy developed from PubMed and then adapted for other databases. We plan to search the reference lists of eligible articles and contact the corresponding authors of papers for missing information.

Search strategy

We will use the search strategy of the previous Cochrane review by Clar et al (online supplemental appendices 1 and 2). Keywords of ‘Influenza Vaccines’ and ‘Cardiovascular Diseases’ will be used to capture observational studies. Auto alerts will be configured to receive monthly updates.

Study records

Data management

The search results from all databases will be imported into the reference management software EndNote VX.9. Duplicated reports from the same study will be removed. The unique records will be imported to the study screening and data extraction software Covidence.

Selection process

Predefined inclusion and exclusion criteria will be used for screening. After title and abstract screening, full texts will be downloaded for the remaining studies. Study tags will be created to mark predefined eligibility criteria for easier screening and post hoc checks. The entire selection process will be conducted independently by two reviewers. Conflicts or disagreements between the two reviewers will be resolved by a third reviewer. A screening process flow chart will be presented as per PRISMA recommendation.

LSR-specific indicators will also be reported. These will include, for example, LSR version number, time since preceding update, number of citations screened for the LSR update period, number of identified newly published eligible primary study protocols, number of identified newly published eligible primary studies and disposition of newly identified eligible primary studies (ie, incorporated or not). Changes in LSR methodology compared with previous versions will be reported. Any changes in statistical results, certainty of evidence and conclusions from previous iterations will be highlighted in the LSR report. Differences between the protocol and the review will be recorded and justified.

Data collection process

Data will be extracted and entered into a predefined data extraction form. Data extraction will be done by two authors independently, with discrepancies resolved by a third author. The data extraction form will be reviewed by the entire review team and piloted for the first three studies before its roll-out.

Data items

The following data elements will be extracted:

- General information: title, authors, author contact details, year of publication, journal, language, type of paper (original research, protocol, review and editorial).
- Population: inclusion and exclusion criteria, sampling and recruitment methods, study population characteristics and comparability between groups at baseline (age, sex, socioeconomic status, country, inpatient or outpatient, comorbidity and concomitant treatment regimen other than vaccination). General population or population with pre-existing CVD, and the disease subtype (MI, HF, stroke, etc) if with pre-existing CVD. COVID-19 status.
Intervention: vaccine type, valency, dose, administration route, timing of vaccination, number of participants in intervention group, duration of follow-up. Level of the match of influenza vaccines to circulating strains.

Comparator: placebo, or no vaccine, number of participants in the control group, overall follow-up, duration of follow-up.

Outcomes: definition, time points measured, number of outcome events in intervention and control groups, incidence rate in intervention and control groups, prevalence in intervention and control groups, unadjusted and adjusted effect measures (OR, RR or HR), covariates used for adjustment, effect size (point estimate, SE or SD or CI), missing data, reason for missingness, approach to handling missing data, statistical methods, randomisation process. Dropout rate, loss to follow-up rate and adverse event rate in intervention and control groups.

Study design and methods: study type, registration number, country and setting, recruitment time, date of first participant (or cluster) randomised, date of last participant (or cluster) randomised, date of last participant followed up for outcomes in RCTs, date of last participant recruitment, date of last participant followed up for outcomes in observational studies, vaccination date, hemisphere, match of the influenza vaccine strains to those circulating, reporting time, study duration, study objectives.

Study funding and conflict of interest.

Effect sizes will be extracted as reported in the source article, and transformed when appropriate. In case of missing information from an included paper, an attempt of contacting the authors to obtain these data will be made.

Assessment of risk of bias in individual studies

We will apply version 2 of Cochrane risk-of-bias tool (RoB 2) to included RCTs. Through RoB 2, studies will be assessed across a number of domains, including random allocation sequence, allocation sequence concealment, blinding, outcome assessment, missing data and analysis methods, to classify studies into a ‘low risk of bias’, ‘some concerns of risk’ or ‘high risk of bias’ categories.

For observational studies, we will apply the Risk of Bias in Non-randomized Studies–of Interventions (ROBINS-I). ROBINS-I assesses a number of domains, including confounding, selection bias, baseline comparability between groups, intervention fidelity, outcome measurement and selection of reported results. Studies will be classified into categories reflecting risks of ‘low’, ‘moderate’ and ‘serious’ bias. Two authors will perform the RoB assessment with consensus.

Data synthesis

Narrative synthesis

A narrative summary of the effect of influenza vaccines on outcomes will be provided. Study characteristics (design, participants, intervention, comparator, outcomes, methods, funding and conflict of interest) will be presented in a table.

Criteria for quantitative data synthesis

We will perform separate meta-analyses pooling results from observational studies and RCTs. We will evaluate differences between the two sets of results, although we expect observational studies to report higher effect sizes compared with RCTs. We plan to carry out a Hartung-Knapp-Sidik-Jonkman random effects meta-analysis whenever it is feasible to do so. If it is not feasible, we will revert to narrative review (for instance, if only one study reported a specific outcome). We will also report pooled effects according to the common (ie, fixed) effect model. To better handle the uncertainty of the various parameters to be estimated (especially the between-study variance) and also considering the prospective nature of this study, we will also perform a Bayesian meta-analysis. This will allow us to calculate the probabilities of the vaccine to be effective. As data accrue, the posterior distribution of the pooled effect will be updated to reflect the information derived until that moment, which will be used as an informative prior distribution of the effect size. Sensitivity analyses will be performed using vague and vaguely informative priors for the effect size and for the between-study heterogeneity.

For binary outcomes, we will use RR with 95% CI (or credible intervals for the Bayesian meta-analysis) to measure the effect of influenza vaccination. For time-to-event data, we will use HR with 95% CI accordingly.

Unit of analysis issues

Analyses will be done at a study level. For cluster randomised trials (including stepped wedge trials, if any), we will ensure the cluster effect has been taken into account. If not, we will inflate SEs using the design effect (which is a function of the average cluster size and intraclass correlation (ICC) coefficient). If the ICC coefficient is not reported, we could ‘borrow’ the ICC from one study and apply to another, or run sensitivity analyses by various design effect inflation factors.

Dealing with missing data

For studies without reported data for an outcome of interest, we will try to obtain this information by contacting the original authors. For studies with a high level of missing outcome data, we will analyse the available data sets and explore the robustness of results by sensitivity analyses for each outcome variable. A high level of missing data is defined as more than 10% data for any variables of interest.

Assessment of heterogeneity

We plan to assess heterogeneity by formal test of heterogeneity and evaluating the proportion of variability attributable to heterogeneity rather than sampling error using the I² statistic. As per the Cochrane Handbook, we will consider values of I² between 50% and 90% as substantial heterogeneity and above 75% as considerable heterogeneity. Subgroup analyses and meta-regression based on the following variables will be used to explore possible reasons of heterogeneity:
Population type (general population, pre-existing CVD population).
- Age groups (if feasible).
- Hospitalised versus outpatient.
- If disease-specific population, then consider the severity of disease, for example, ejection fraction category for patients with HF.
- Non-pandemic years versus 2009/2010 pandemic year if feasible.
- Follow-up length in season and out of season if applicable.
- Influenza season for the Northern Hemisphere is defined from 1 September until 31 May of the following year. Influenza season for the Southern Hemisphere is defined from 1 April until 30 September of the same year.
- Level of the match of influenza vaccines to circulating strains if reported.
- Level of risk of bias.

We plan to investigate the likelihood of selective outcome reporting bias by comparing the study report and its corresponding protocol. If more than 10 studies are finally selected, formal Egger’s regression-based test and eyeball assessment of the funnel plots will be explored to evaluate small-study effects.

Sensitivity analysis
Sensitivity analysis will be applied for excluding studies with high level of missing data or other critical issues identified during the review process. First, we will analyse all the available studies, and then only include studies that are definitely eligible. Results from different scenarios will be compared and reported.

Confidence in cumulative evidence
We will use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to judge the overall quality of all findings. The GRADE system classifies evidence into ‘high quality’, ‘moderate quality’, ‘low quality’ and ‘very low quality’, based on methodology quality, consistency, directness, precision and the risk of reporting bias. The cumulative quality of evidence will be assessed by all authors.

Patient and public involvement
No patient was involved.

DISCUSSION
Main findings of previous reviews
The 2015 Cochrane review included four RCTs (n=1682) of influenza vaccination compared with placebo or no vaccination for preventing cardiovascular mortality in populations with pre-existing CVD. It presented a wide CI around the pooled RR for preventing cardiovascular mortality associated with influenza vaccines (0.45, 95% CI 0.26 to 0.76, p=0.003). The pooled studies had some risk of bias and were of small sample size, which contributed to the wide CI of estimated efficacy. Not enough evidence was available to establish the role of influenza vaccination in the primary prevention of cardiovascular events. With ongoing trials aiming to recruit more than 9000 participants, pooling these results together would substantially contribute to the evidence base.

One more recent systematic review and meta-analysis has been conducted, pooling four RCTs (n=1667) and 12 observational studies (n=235391) and indicating a pooled RR of 0.87 (95% CI 0.80 to 0.94, p<0.001) for major adverse cardiovascular events among patients receiving influenza vaccines versus those receiving no vaccine or a placebo. This systematic review focused on the use of influenza vaccine as a secondary prevention measure for patients with established CVD and extracted articles published through to January 2020.

A contemporary trial Influenza Vaccination After Myocardial Infarction (IAMI, NCT02831608) has even more recently published findings. This trial specifically focused on patients with recent MI (n=2571). Compared with placebo, participants receiving influenza vaccines had a 28% lower risk of all-cause death, MI or stent thrombosis (0.72, 95% CI 0.52 to 0.99). Another trial, Influenza Vaccine to Prevent Adverse Vascular Events (RCT-IVVE, NCT02762851), comparing inactivated influenza vaccine to placebo in patients with HF is ongoing. This trial is expected to report results in 2022. The large sample size of these two more recent trials, relative to previous studies, suggests that their findings are likely to be highly influential on pooled efficacy estimates.

Impact and significance of the review
Although current guidelines recommend populations with pre-existing CVD receive annual influenza vaccinations, there is inconclusive evidence regarding the efficacy and safety of influenza vaccines for preventing death or hospitalisation from CVD. Previous systematic reviews reached uncertain conclusions with a lack of high-quality studies. As large ongoing trials are investigating influenza vaccination for preventing cardiovascular events, new evidence is accumulating and may substantially add to the evidence base. This provides an important opportunity to update current literature on the efficacy of influenza vaccination on cardiovascular mortality and hospitalisation.

The LSR will continuously synthesise the latest research findings so as to inform the public and healthcare professionals. With the most updated evidence regarding the efficacy of influenza vaccination in preventing CVD morbidity and mortality especially in high-risk populations, healthcare providers may be able to make recommendations to individual patients with more certainty. From a public health point of view, the findings may influence vaccine policies in relation to the general and high-risk populations.

This review will also provide important pooled parameters estimates that can also inform subsequent economic evaluations of various vaccines and vaccination strategies.

Registration
This LSR protocol was registered with the International Prospective Register of Systematic Reviews.
Editorial and publication process consideration

LSR versions will be submitted to a peer-reviewed journal accommodating iterative versions of the same systematic review.

Author affiliations
1 Heart Health Research Center, Beijing, China
2 The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
3 Department of Cardiology, Beijing Anzheng Hospital, Capital Medical University, Beijing, China
4 School of Population Health, University of New South Wales, Sydney, New South Wales, Australia
5 BioStatistics & Data Science Division, Meta-Research and Evidence Synthesis, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia

Contributors
All authors have contributed to the final submitted manuscript. GLDT is the lead supervisor of the first author. AP, XD and HL are co-supervisors. BL gave significant input regarding the epidemiology of influenza virus circulation. RL drafted the initial manuscript and received guidance regarding the content area and methodology from all authors. CW is the second reviewer. All authors have read and agreed to the final manuscript.

Funding
This research is being funded by an Australian Government Research Training Program (RTP) Scholarship.

Competing interests
None declared.

Patient and public involvement
Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is

REFERENCES
27. The Database of Abstracts of Reviews of Effects (DARE), Centre for reviews and dissemination, University of York. Available: https://www.crd.york.ac.uk/CRDWeb/
28. The Economic Evaluation Database (EED). Centre for reviews and dissemination, University of York. Available: https://www.crd.york.ac.uk/CRDWeb/
29. Health Technology Assessment (HTA), Centre for reviews and dissemination, University of York. Available: https://www.crd.york.ac.uk/CRDWeb/
30. Covidence [computer program].
39 International prospective register of systematic reviews (PROSPERO). Centre for reviews and dissemination, University of York. Available: https://www.crd.york.ac.uk/prospero/
Appendix 1. Search strategies 2013 - cardiovascular disease

The Cochrane Library

#1 MeSH descriptor: [Influenza Vaccines] this term only
#2 (influenza* near vaccin*)
#3 (influenza* near immuni*)
#4 (flu near immuni*)
#5 (flu near vaccin*)
#6 (#1 or #2 or #3 or #4 or #5)
#7 MeSH descriptor: [Cardiovascular Diseases] explode all trees
#8 cardio*
#9 cardia*
#10 heart*
#11 coronary*
#12 angina*
#13 ventric*
#14 myocardi*
#15 pericard*
#16 isch?em*
#17 emboli*
#18 arrhythmia*
#19 thrombo*
#20 atrial next fibrillat*
#21 tachycardi*
#22 endocardi*
#23 (sick next sinus)
#24 MeSH descriptor: [Stroke] explode all trees
#25 (stroke or stokes)
#26 cerebrovasc*
#27 cerebral next vascular
#28 apoplexy
#29 (brain near/2 accident*)
#30 (brain* or cerebral or lacunar) near/2 infarct*)
#31 MeSH descriptor: [Hypertension] explode all trees
#32 hypertensi*
#33 (peripheral next arter* next disease*)
#34 (high or increased or elevated) near/2 blood pressure
#35 MeSH descriptor: [Hyperlipidemias] explode all trees
#36 hyperlipid*
#37 hyperlip?emia*
#38 hypercholesterol*
#39 hypercholesterol?emia*
#40 hyperlipoprotein?emia*
#41 hypertriglycerid?emia*
#42 MeSH descriptor: [Arteriosclerosis] explode all trees
MEDLINE Ovid

1. Influenza Vaccines/
2. (influenza$ adj3 immuni$).tw.
3. (flu adj3 vaccin$).tw.
5. (influenza adj3 vaccin$).tw.
6. flumist.tw.
7. (laiv adj2 vaccin*).tw.
8. (caiv-t adj2 vaccin*).tw.
9. or/1-8
10. exp Cardiovascular Diseases/
11. cardio*.tw.
12. cardia*.tw.
13. heart*.tw.
15. angina*.tw.
16. ventrie*.tw.
17. myocard*.tw.
18. pericard*.tw.
20. emboli*.tw.
21. arrhythm*1.tw.
22. thrombo*.tw.
23. atrial fibrillat*.tw.
24. tachycard*1.tw.
25. endocard*.tw.
27. exp Stroke/
28. (stroke or stokes).tw.
29. cerebrovasc*.tw.
30. cerebral vascular.tw.
31. apoplexy.tw.
32. (brain adj2 accident*).tw.
33. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
34. exp Hypertension/
35. hypertensi*.tw.
36. peripheral arter* disease*.tw.
37. ((high or increased or elevated) adj2 blood pressure).tw.
38. exp Hyperlipidemias/
39. hyperlipid*.tw.
40. hyperlipemia*.tw.
41. hypercholesterol*.tw.
42. hypercholesteremia*.tw.
43. hyperlipoprotein?emia*.tw.
44. hypertriglycerid?emia*.tw.
45. exp Arteriosclerosis/
46. exp Cholesterol/
47. cholesterol.tw.
49. Blood Pressure/
50. blood pressure.tw.
51. or/10-50
52. 9 and 51
53. randomized controlled trial.pt.
54. controlled clinical trial.pt.
55. randomized.ab.
56. placebo.ab.
57. drug therapy.fs.
58. randomly.ab.
59. trial.ab.
60. groups.ab.
61. 53 or 54 or 55 or 56 or 58 or 59 or 60
62. exp animals/ not humans.sh.
63. 61 not 62
64. 52 and 63

EMBASE Ovid

1. influenza vaccine/
2. (influenza$ adj3 immuni$).tw.
3. (flu adj3 vaccin$).tw.
5. (influenza adj3 vaccin$).tw.
6. flumist.tw.
7. (laiv adj2 vaccin*).tw.
8. (caiv-t adj2 vaccin*).tw.
9. or/1-8
10. exp cardiovascular disease/
11. cardio*.tw.
12. cardia*.tw.
13. heart*.tw.
<table>
<thead>
<tr>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>15. angina*.tw.</td>
</tr>
<tr>
<td>16. ventric*.tw.</td>
</tr>
<tr>
<td>17. myocard*.tw.</td>
</tr>
<tr>
<td>18. pericard*.tw.</td>
</tr>
<tr>
<td>20. emboli*.tw.</td>
</tr>
<tr>
<td>21. arrhythm*.tw.</td>
</tr>
<tr>
<td>22. thrombo*.tw.</td>
</tr>
<tr>
<td>23. atrial fibrillat*.tw.</td>
</tr>
<tr>
<td>24. tachycardi*.tw.</td>
</tr>
<tr>
<td>25. endocardi*.tw.</td>
</tr>
<tr>
<td>27. exp cerebrovascular disease/</td>
</tr>
<tr>
<td>28. (stroke or stokes).tw.</td>
</tr>
<tr>
<td>29. cerebrovasc*.tw.</td>
</tr>
<tr>
<td>30. cerebral vascular.tw.</td>
</tr>
<tr>
<td>31. apoplexy.tw.</td>
</tr>
<tr>
<td>32. (brain adj2 accident*).tw.</td>
</tr>
<tr>
<td>33. ((brain* or cerebral or lacunar) adj2 infarct*).tw.</td>
</tr>
<tr>
<td>34. exp hypertension/</td>
</tr>
<tr>
<td>35. hypertensi*.tw.</td>
</tr>
<tr>
<td>36. peripheral arter* disease*.tw.</td>
</tr>
<tr>
<td>37. ((high or increased or elevated) adj2 blood pressure).tw.</td>
</tr>
<tr>
<td>38. exp hyperlipidemia/</td>
</tr>
<tr>
<td>39. hyperlipid*.tw.</td>
</tr>
<tr>
<td>40. hyperlip?emia*.tw.</td>
</tr>
<tr>
<td>41. hypercholesterol*.tw.</td>
</tr>
<tr>
<td>42. hypercholester?emia*.tw.</td>
</tr>
<tr>
<td>43. hyperlipoprotein?emia*.tw.</td>
</tr>
<tr>
<td>44. hypertriglycerid?emia*.tw.</td>
</tr>
<tr>
<td>45. exp Arteriosclerosis/</td>
</tr>
<tr>
<td>46. exp Cholesterol/</td>
</tr>
<tr>
<td>47. cholesterol.tw.</td>
</tr>
<tr>
<td>49. Blood Pressure/</td>
</tr>
<tr>
<td>50. blood pressure.tw.</td>
</tr>
<tr>
<td>51. or/10-50</td>
</tr>
<tr>
<td>52. 9 and 51</td>
</tr>
<tr>
<td>53. random$.tw.</td>
</tr>
<tr>
<td>54. factorial$.tw.</td>
</tr>
<tr>
<td>55. crossover$.tw.</td>
</tr>
<tr>
<td>56. cross over$.tw.</td>
</tr>
<tr>
<td>57. cross-over$.tw.</td>
</tr>
<tr>
<td>58. placebo$.tw.</td>
</tr>
<tr>
<td>59. (doubl$ adj blind$).tw.</td>
</tr>
</tbody>
</table>
60. (singl$ adj blind$).tw.
61. assign$.tw.
62. allocat$.tw.
63. volunteer$.tw.
64. crossover procedure/
65. double blind procedure/
66. randomized controlled trial/
67. single blind procedure/
68. 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67
69. (animal/ or nonhuman/) not human/
70. 68 not 69
71. 52 and 70

Web of Science

#12 #11 AND #10
#11 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-
over*)
#10 #9 AND #1
#9 #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2
#8 TS=(hyperlipid* OR hyperlip?emia* OR hypercholesterol* OR hypercholester?emia* OR
hyperlipoprotein?emia* OR hypertriglycerid?emia*)
#7 TS=("high blood pressure")
#6 TS=(hypertensi* OR "peripheral arter* disease")
#5 TS=(stroke OR stokes OR cerebrovasc* OR cerebral OR apoplexy OR (brain SAME
accident*) OR (brain SAME infarct*))
#4 TS=(("atrial fibrillat*" OR tachycardi* OR endocardi*)
#3 TS=(pericard* OR isch?em* OR emboli* OR arrhythmi* OR thrombo*)
#2 TS=(cardio* OR cardia* OR heart* OR coronary* OR angina* OR ventric* OR myocard*)
#1 TS=((influenza* OR flu OR laiv OR caiv-t) NEAR/3 (immuni* OR vaccin*)) OR flumist)

Limited PubMed search 20 February 2015

((vaccine* OR vaccinat*) AND (influenza OR flu) AND (cardiovascular OR heart OR coronary
OR stroke)) in PubMed Clinical Queries

Similar (adapted) search in www.controlled-trials.com and www.clinicaltrials.gov

Appendix 2. Search strategies 2008 - coronary heart disease

CENTRAL (2007, Issue 4)

#1 INFLUENZA VACCINE
#2 (influenza* near vaccin*)
#3 (influenza* near immuni*)
#4 (flu near immuni*)
#5 (flu near vaccin*)
#6 (#1 or #2 or #3 or #4 or #5)
#7 CARDIOVASCULAR DISEASES
#8 heart
#9 coronary
#10 cardiac
#11 myocardial
#12 cardiovascular
#13 angina
#14 (#7 or #8 or #9 or #10 or #11 or #12 or #13)
#15 (#6 and #14)

**MEDLINE (to January 2008)**

1 Influenza Vaccine/
2 (influenza$ adj3 immuni$).tw.
3 (flu adj3 vaccin$).tw.
4 (flu adj3 immuni$).tw.
5 (influenza adj3 vaccin$).tw.
6 or/1-5
7 exp cardiovascular diseases/
8 myocardial.tw.
9 angina.tw.
10 coronary.tw.
11 heart.tw.
12 cardiac.tw.
13 cardiovascular.tw
14 or/7-13
15 6 and 14
16 randomized controlled trial.pt.
17 controlled clinical trial.pt.
18 Randomized controlled trials/
19 random allocation/
20 double blind method/
21 single-blind method/
22 or/16-21
23 exp animal/ not humans/
24 22 not 23
25 clinical trial.pt.
26 exp Clinical trials/
27 (clinn$ adj25 trial$).ti,ab.
28 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.
29 placebos/
30 placebo$ .ti,ab.
31 random$.ti,ab.
32 research design/
33 or/25-32
34 33 not 23
35 34 not 24
36 comparative study.pt.
37 exp evaluation studies/
38 follow up studies/
39 prospective studies/
40 (control$ or prospectiv$ or volunteer$).ti,ab.
41 or/36-40
42 41 not 23
43 42 not (24 or 35)
44 24 or 35 or 43
45 15 and 44
46 limit 45 to yr="2005 - 2008"

EMBASE (to January 2008)
1 Influenza Vaccine/
2 (influenza$ adj3 immuni$).tw.
3 (flu adj3 vaccin$).tw.
4 (flu adj3 immuni$).tw.
5 (influenza adj3 vaccin$).tw.
6 or/1-5
7 exp cardiovascular disease/
8 myocardial.tw.
9 angina.tw.
10 coronary.tw.
11 heart.tw.
12 cardiac.tw.
13 cardiovascular.tw.
14 or/7-13
15 6 and 14
16 clinical trial/
17 random$.tw.
18 randomized controlled trial/
19 trial$.tw.
20 follow-up.tw.
21 double blind procedure/
22 placebo$.tw.
23 placebo/
24 factorial$.ti,ab.
25 (crossover$ or cross-over$).ti,ab.
26 (double$ adj blind$).ti,ab.
27 (singl$ adj blind$).ti,ab.
28 assign$.ti,ab.
29 allocat$.ti,ab.
30 volunteer$.ti,ab.
31 Crossover Procedure/
32 Single Blind Procedure/
33 or/16-32
34 15 and 33
35 limit 34 to yr="2005 - 2008"